investors & media

There are currently no events to display.

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

stock quote

Copyright West LLC. Minimum 15 minutes delayed.

press releases


  CAMBRIDGE, Mass. and BAGSVÆRD, Denmark --(BUSINESS WIRE)--Oct. 9, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome   editing treatments for genetic diseases,

Read more

  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed William R. Sellers , M.D. to its Board of Directors. “I’m excited to welcome Bill to the Board to help navigate an important stage in bluebird’s evolution,” said Nick

Read more

Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 18, 2019-- bluebird bio, Inc.

Read more